Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

Muscle Vibration as a Countermeasure Against Hypoactivity-induced

NCT07021079 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2025-06-16
Last updated
2026-05-26

Condition(s) studied

Vibration TherapyHealthy Volunteer StudyHypoactivity

Investigational drug(s) / intervention(s)

Focal muscle vibrationNO Focal muscle vibration

Focal muscle vibration: focal muscle vibration sessions, using small and portable vibrator devices.

NO Focal muscle vibration: The control group will not receive any intervention.

Study summary

Muscle deconditioning, characterized by a loss of muscle mass and strength, is a frequent consequence of prolonged lower limb unloading. Beyond muscle mass loss, reduced neural drive contributes significantly to strength decline, highlighting the need for interventions targeting neuromuscular function during immobilization. Focal muscle vibration (FMV) has shown promise in modulating neuromuscular excitability by activating muscle spindle afferents and inducing cortical adaptations. Chronic use of FMV has been associated with significant strength gains and improved neural command. This makes FMV an effective rehabilitation tool. Its simplicity and non-invasiveness further make it a practical countermeasure.

Eligibility

Sex
ALL
Min age
19 Years
Max age
45 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Men and women. * Aged 18 to 45 years. * Body Mass Index (BMI) between 18,5 and 24,9 kg/m². * Engaging in at least 1.5 hours per week of physical activity (e.g., brisk walking, running, swimming, cycling). * Provided informed consent after receiving detailed information about the study. * Affiliated with or beneficiaries of a social security system Exclusion Criteria: * Chronic cardiovascular, neuromuscular, bone, metabolic, and/or inflammatory disorders. * Personal history and/or risk factors for thrombosis. * Use of antidepressant medications. * Use of neuroactive substances likely to alter corticospinal excitability (e.g., hypnotics, antiepileptics, psychotropics, muscle relaxants) during the study. * Recent bone or ligament trauma within the past 12 months. * Inability to perform the physical efforts required for the study. * Recent participation in a sporting competition or intense, unusual physical activity within the past month. * Corticosteroid treatment within the past 3 months. * Any skin lesions at the planned vibrator application site. * Simultaneous participation in another interventional medical study. * Pregnant or breastfeeding women. * Individuals unable to understand the purpose and conditions of the study or unable to provide informed consent. * Individuals deprived of liberty or under guardianship

Primary outcome measure(s)

  • Isometric force measurement — Day 1, 7, 14, 28, 33
    Maximal isometric force (% decrease) in knee extension of the immobilized leg will be evaluated

Trial sites (1)

FacilityCityRegionStatus
Centre Hospitalier Universitaire Saint-Etienne France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07021079 on ClinicalTrials.gov ↗ ← All trials in France